About Intercytex
Intercytex is a Healthcare company based in Manchester (United Kingdom) founded in 2000 by Paul Kemp. It operates as a developer of cell-based therapies for the repair and regeneration of skin and hair. Intercytex has raised $13 million across 2 funding rounds from investors including 3i Group, Avlar Bioventures and Merlin Biosciences. The company has 1 employees. Its chief executive is Paul Kemp. Its focus areas include Life Sciences, Dermatology, Drugs and Aesthetics. Its legal entity is Intercytex Limited. Its competitors include Amyris, Revance Therapeutics, Avidity Biosciences, Arbor Biotechnologies and Univercells and 5 more; 9 of its 10 listed competitors have raised funding.
Company details
Intercytex was founded in 2000 in Manchester, United Kingdom, and operates in the biotechnology sector focused on regenerative medicine. A proprietary integrated cell technology platform is utilized to create living, human cell-based products. The product pipeline encompasses VAVELTA for facial rejuvenation and skin damage repair, SHEF-1-Stem Cell Line targeting age-related macular degeneration, ICX-TRC for hair regeneration, and ICX-SKN as a skin graft replacement for burns and wounds.
- Headquarters Manchester, United Kingdom
- Employees 1
- Founders Paul Kemp
- SectorsHealthcare
- Website intercytex.com
- Social LinkedIn
- Legal Name Intercytex Limited
- Total Equity Funding$13M (USD)
in 2 rounds
- Latest Funding Round$12M (USD), Series A
Aug 2005
- Investors3i Group
& 4 more
- Employee Count1
Funding Insights of Intercytex
Intercytex has successfully raised a total of $13M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $12 million completed in August 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13M
- Total Rounds 2
- Last Round Series A — $12M
- First Round $1M
(Aug 2003)
- Investors Count 5
All 2 funding rounds of Intercytex with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2005 | $12M | Series A | – | Avlar Bioventures, Merlin Biosciences | |
| Aug 2003 | $1M | Seed | – | Scottish Equity Partners | – |
5 investors in total: 5 institutional.
Investors in Intercytex
Intercytex has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include 3i Group, Avlar Bioventures and Merlin Biosciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | avlar.com | - | |
- | – | merlin-biosciences.com | - | |
Private equity firm focused on mid-market businesses | 1945 | 3i.com | London, United Kingdom | |
Online slot gaming services are offered by ng24h platform. | – | nifventures.com | - | |
Venture capital firm focused on tech companies | – | sep.co.uk | London, United Kingdom |
Investor details for Intercytex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Intercytex
1 people are tracked at Intercytex (1 in leadership); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
Paul Kemp | Founder & CEO | Leadership |
Complete people profiles for Intercytex
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Intercytex
3 dated milestones of Intercytex across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Intercytex is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Series A, of $12.0M.
Competitors of Intercytex
Intercytex has 10 listed competitors in our database, 9 of them funded. They include Amyris, Revance Therapeutics, Avidity Biosciences, Arbor Biotechnologies and Univercells, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| amyris.com | 2003 | Emeryville, United States | $487.2M | 747 | Developer of renewable products for industrial solutions | |
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| arbor.bio | 2016 | Cambridge, United States | $304.1M | 117 | Genomic technologies and drug discovery platforms are provided. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| relaytx.com | 2016 | Cambridge, United States | $520M | 261 | Drug discovery platform is developed to study protein motion. | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. |
Detailed competitors of Intercytex
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Intercytex
Websites that share an audience with Intercytex (intercytex.com).
Websites whose visitors overlap most with Intercytex. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| stemcellsinc.com | 100% | – | – | View details | |
| cellerant.com | 100% | – | – | View details | |
| neurogeneration.com | 100% | – | – | View details | |
| cognatebioservices.com | 100% | – | – | View details | |
celle.com | celle.com | 100% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 17 similar websites and full traffic analytics for Intercytex
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 17 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
10 companies that operate in the same segment as Intercytex (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Intercytex
Complete news archive for Intercytex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Intercytex
Intercytex was founded in 2000 and raised its 1st funding round 3 years after it was founded.
Intercytex is headquartered in Manchester, United Kingdom. It is registered at Manchester, Greater Manchester, United Kingdom.
Paul Kemp is the current CEO of Intercytex. They have also founded this company.
Intercytex is a funded company, having raised a total of $13M across 2 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Aug 2003.
Intercytex has 1 employees.
Intercytex was founded in 2000 in Manchester, United Kingdom, and operates in the biotechnology sector focused on regenerative medicine. A proprietary integrated cell technology platform is utilized to create living, human cell-based products. The product pipeline encompasses VAVELTA for facial rejuvenation and skin damage repair, SHEF-1-Stem Cell Line targeting age-related macular degeneration, ICX-TRC for hair regeneration, and ICX-SKN as a skin graft replacement for burns and wounds.
Intercytex's top competitors include Revance Therapeutics, Sutro Biopharma and Avidity Biosciences.
Intercytex has 5 investors. Key investors include 3i Group, Avlar Bioventures, Merlin Biosciences, ng24h, and Scottish Equity Partners.
Intercytex operates through Intercytex Limited.